24 Jan 2020 07:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Grant of Options under Company EMI Plan
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that certain Directors and PDMRs were granted options on 23 January 2020 (the "Grant Date") to subscribe for an aggregate of 3,150,000 ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 15.4 pence per Ordinary Share (the "Options"). The Options are being granted under the Company's 2020 EMI Plan. The Options shall have a two-year vesting period, after which the Option may then be exercised in whole or in part in accordance with the Rules of the Plan.
A full break down of Directors and PDMRs being granted the Options is provided below:
Name | Director or PDMR | Current Options | Proposed Option award | Total Options after award |
Colin King | Chief Executive Officer | 1,200,000 | 950,000 | 2,150,000 |
Kieron Harbinson | Group Finance Director | 940,000 | 750,000 | 1,690,000 |
Jag Grewal | Group Commercial Director | 910,000 | 500,000 | 1,410,000 |
Edward Valente | PDMR | 300,000 | 100,000 | 400,000 |
Mike Gordon | PDMR | 290,000 | 100,000 | 390,000 |
Jamie Yexley | PDMR | 225,000 | 100,000 | 325,000 |
Patrick Breen | PDMR | 45,000 | 150,000 | 195,000 |
Angela Robertson | PDMR | 25,000 | 100,000 | 125,000 |
John Bannister | PDMR | 230,000 | 100,000 | 330,000 |
Derek Brady | PDMR | 0 | 150,000 | 150,000 |
Jill Hepburn | PDMR | 0 | 150,000 | 150,000 |
Total |
| 4,165,000 | 3,150,000 | 7,315,000 |
The Options issued to Colin King, Kieron Harbinson and Jag Grewal contain an additional performance condition which states the Option shall not be capable of being exercised unless and until the middle-market quotation of a Share is equal or greater than 30p at any time on or after the second anniversary of the Grant Date, after which the Option may then be exercised in whole or in part in accordance with the Rules of the Plan as if no further Performance Condition applied.
Following the Option award, there are a total of 13,645,406 unexercised options over Ordinary Shares in the Company, representing 9.07 per cent. of the issued share capital.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director |
|
|
|
|
|
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Hannah Boros (Corporate Finance) |
|
Camille Gochez (Corporate Broking) |
|
|
|
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Kieron Harbinson | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | Group Finance Director | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Colin King | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | CEO | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Jag Grewal | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | Group Commercial Director | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Edward Valente | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Mike Gordon | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Jamie Yexley | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Patrick Breen | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Angela Robertson | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | John Bannister | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Derek Brady | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||
a) | Name | Jill Hepburn | ||||
2 | Reason for the notification |
| ||||
a) | Position / status | PDMR | ||||
| Initial notification / amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Omega Diagnostics Group PLC | ||||
b) | LEI | 2138007U9P4BTZTYIR92 | ||||
4 | Details of the transaction(s): section to be prepared for (i) each type of instrument; (ii) each type of transaction; (iii) each date and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 4p each ("Ordinary Shares") | ||||
| Identification code | ISIN: GB00B1VCP282 | ||||
b) | Nature of transaction | Grant of Options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information | As above | ||||
e) | Date of the transaction | 23 January 2020 | ||||
f) | Place of the transaction | N/a | ||||